Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof

Patent metadata

Field	Value
Publication number	US-11339442-B2
Application number	US-201616061546-A
Country	US
Kind code	B2
Filing date	Dec 14, 2016
Priority date	Dec 14, 2015
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

The present application generally to the diagnosis and treatment of diseases resulting from the alteration of chromatin boundaries between topologically-associated domains. In particular, the present application relates to detection of mutations causing DNA hypermethylation phenotypes, CpG methylation within CTCF binding motifs, and aberrant gene expression caused by altered chromatin topology. Applicants show that IDH mutant gliomas exhibit hyper-methylation at CTCF binding sites, compromising binding of this methylation-sensitive insulator protein. Applicants also demonstrate that loss of CTCF at a domain boundary permits a constitutive enhancer to aberrantly interact with the receptor tyrosine kinase gene PDGFRA, a prominent glioma oncogene. Thus, Applicants have uncovered that IDH mutations may promote gliomagenesis by disrupting chromosomal topology and allowing aberrant regulatory interactions that induce oncogene expression.

First claim

What is claimed is:

1. A method of detecting and treating a glioma in a subject, the method comprising:
detecting in a brain biopsy sample obtained from the subject altered chromatin topology, relative to an appropriate control, within a chromatin region comprising at least one distinct topologically-associated domain partitioned by insulator sites, wherein at least one of said insulator sites comprises a CpG dinucleotide within a CTCF binding motif, and wherein the chromatin region comprises an oncogene selected from the group consisting of PDGFRA and FIP1L1, thereby identifying the subject as having a glioma, and
administering a glioma therapy to the subject.

2. The method according to claim 1 , wherein the chromatin region comprises a regulatory element.

3. The method according to claim 2 , wherein the regulatory element is an enhancer.

4. The method according to claim 1 , wherein the subject is in cancer remission, has a genetic disorder which predisposes the subject to cancer, or has been exposed to a carcinogen.

5. The method according to claim 4 , wherein said genetic disorder is Ollier Disease, Mafucci syndrome, Carney-Stratakis Syndrome, or a variant of Cowden Syndrome which predisposes the subject to breast or thyroid cancer.

6. The method according to claim 1 , wherein detecting altered chromatin topology comprises detecting 5-methyl cytosine at the CpG dinucleotide.

7. The method according to claim 1 , wherein detecting altered chromatin topology comprises detecting 5-hydroxymethylcytosine at the CpG dinucleotide.

8. The method according to claim 1 , further comprising detecting a gain of function mutation in the gene encoding isocitrate dehydrogenase (IDH) or a loss of function mutation in a gene encoding a succinate dehydrogenase.

9. The method according to claim 1 , wherein said glioma is an oligoastrocytoma or a glioblastoma.

10. The method according to claim 1 , wherein the oncogene is PDGFRA.

11. The method according to claim 1 , wherein altered chromatin topology is detected by chromosome conformation capture (3C), DNA hypersensitivity, CTCF binding, methylation specific PCR, Ms-SNuPE, bisulfate sequencing, methylation sensitive restriction digest, nanopore sequencing or DNA FISH.

12. The method according to claim 1 , wherein the oncogene is FIP1L1.

13. The method according to claim 1 , wherein the control is a biological sample obtained from a subject known not to have glioma.

14. The method according to claim 1 , wherein the glioma therapy comprises a pharmaceutical composition comprising an inhibitor of the oncogene, optionally wherein said inhibitor is selected from the group consisting of imatinib, crenolanib and dasatinib.

15. The method according to claim 1 , wherein the glioma therapy comprises a pharmaceutical composition comprising an inhibitor of a dehydrogenase, optionally a pharmaceutical composition comprising an inhibitor of isocitrate dehydrogenase (IDH).

16. The method according to claim 1 , wherein the glioma therapy comprises a pharmaceutical composition comprising an agent that edits DNA sequence or modulates DNA methylation within one or more of the insulator sites, optionally wherein the agent is selected from the group consisting of a CRISPR-Cas system agent, a TALE agent and a Zinc-finger agent.

17. The method according to claim 1 , wherein the glioma therapy comprises a pharmaceutical composition comprising two or more agents selected from the group consisting of an inhibitor of the oncogene, an inhibitor of a dehydrogenase and an agent that alters the topology of a chromatin domain, optionally wherein said pharmaceutical composition is administered sequentially, optionally wherein the agent that alters the topology of a chromatin domain is administered before the inhibitor of the dehydrogenase.

18. The method according to claim 1 , wherein the subject exhibits a DNA hypermethylation phenotype.

19. The method according to claim 1 , wherein the glioma therapy comprises a pharmaceutical composition comprising a DNA targeting agent, optionally wherein the DNA targeting agent is a CRISPR-Cas system agent, a TALE agent, or a Zinc-finger agent, optionally wherein the CRISPR-Cas system agent comprises an enzymatically inactive CRISPR enzyme, optionally wherein the enzymatically inactive CRISPR enzyme is fused to a functional domain or the CRISPR system comprises a guide RNA including a transcript recruitment sequence configured to recruit a functional domain, optionally wherein the functional domain is a repressor, activator, DNA modifying enzyme or histone modifying enzyme, optionally wherein the agent is inducible.

20. The method according to claim 1 , wherein the altered chromatin topology comprises a disruption in two or more topologically-associated domains such that the domains exhibit aberrant interactions as compared to chromatin from a normal, non-cancerous subject, optionally wherein at least one insulator site within a boundary at each of the two or more topologically-associated domains exhibits decreased CTCF binding as compared to chromatin from a normal, non-cancerous subject.

21. The method according to claim 1 , wherein the altered chromatin topology is the result of decreased binding of CTCF as compared to a normal, non-cancerous cell, optionally wherein aberrant interactions between topologically-associated domains result in altered gene expression, optionally wherein the aberrant interactions are aberrant enhancer-gene interactions, optionally wherein the topologically-associated domains are adjacent.

22. The method according to claim 1 , wherein the glioma therapy comprises a pharmaceutical composition comprising dCas9 fused to a functional domain, optionally wherein the functional domain is a repressor protein, optionally wherein the repressor protein is KRAB.

23. The method of claim 1 , wherein one or more of the insulator sites is enriched in H3K9me3.

24. A method of identifying and treating glioma progression in a subject diagnosed with glioma or a genetic disorder which predisposes the subject to glioma, the method comprising:
detecting in a brain biopsy sample obtained from the subject after diagnosis an increase in altered chromatin topology within a PDGFRA or FIP1L1 gene of human chromosome 4: 53.7-55.4 Mb as compared to an appropriate control, thereby identifying the subject as having glioma progression, and
administering a glioma therapy to the subject.

25. The method according to claim 24 , wherein the chromatin region comprises a regulatory element, optionally wherein the regulatory element is an enhancer.

26. The method according to claim 24 , wherein said human chromosome 4: 53.7-55.4 Mb comprises at least one distinct topologically-associated domain partitioned by insulator sites, wherein at least one of said insulator sites comprises a CpG dinucleotide within a CTCF binding motif, and wherein the chromatin region comprises an oncogene, and wherein detecting altered chromatin topology comprises detecting 5-methyl cytosine at the CpG dinucleotide and/or detecting 5-hydroxymethylcytosine at the CpG dinucleotide.

27. The method according to claim 24 , further comprising detecting a gain of function mutation in the gene encoding isocitrate dehydrogenase (IDH) or a loss of function mutation in a gene encoding a succinate dehydrogenase.

28. The method according to claim 24 :
wherein said glioma is an oli

Assignees

• Massachusetts Gen Hospital

Inventors

• Bernstein Bradley
• Drier Yotam
• Flavahan William
• Tarjan Daniel

Classifications

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6841

  In situ hybridisation · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6809

  Methods for determination or identification of nucleic acids involving differential detection · CPC title

• C12Q2600/154

  Methylation markers · CPC title